Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13961130 | 0.87 | AAK1 (0.50) | FUCA1CHRM1CHRM2CHRM3RAB9A | |
| SCHEMBL24398303 | 0.86 | CHRM1 (0.47) | FUCA1CHRM1CHRM2CHRM3TDP1 | |
| SCHEMBL13931009 | 0.82 | FUCA1 (0.55) | FUCA1TDP1POLBRAB9ANPC1 | |
| SCHEMBL13961132 | 0.79 | CHRM1 (0.42) | FUCA1CHRM1CHRM2CHRM3RAB9A | |
| Hydrochloric Acid SCHEMBL5776216 | 0.79 | RAB9A (0.54) | FUCA1POLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL4254635 | 0.76 | RAB9A (0.47) | FUCA1POLBRAB9A | |
| SCHEMBL4254638 | 0.76 | RAB9A (0.47) | FUCA1POLBRAB9A | |
| SCHEMBL4254896 | 0.75 | RAB9A (0.59) | FUCA1TDP1POLBRAB9ANPC1 | |
| SCHEMBL13930979 | 0.74 | RAB9A (0.47) | FUCA1CHRM3POLBRAB9A | |
| SCHEMBL3809292 | 0.74 | GPR119 (0.54) | POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164491-A1 | PIPERIDINE-4-ACETIC ACID DERIVATIVES AND THEIR USE | Euroscreen S.A. (BE) | 2010-03-24 | — | — | EP | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009010477-A1 | PIPERIDINE-4-ACETIC ACID DERIVATIVES AND THEIR USE | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010477-A1 | PIPERIDINE-4-ACETIC ACID DERIVATIVES AND THEIR USE | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | FUCA1 3074/4885CHRM1 379/4885CHRM2 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.